Companies
Chronic pelvic pain is a debilitating condition, that impacts over 15 million US women and costs over $39 Billion each year to manage. V-Flow medical has developed a trio of products that target the root cause of chronic pelvic pain, allowing millions of women to avoid opioid use and restart living a normal, pain free life. The V-Flow team has successfully scaled, multiple start-up medical device companies in various clinical disciplines with a combined exit value of over $4B. We have developed a broad IP portfolio covering both device design and method of application. A recent landscaping identified no competing IP for our indication of use. We have tested our beta prototypes and are initiating animal models ahead of a planned first in human investigation in Q1 2023. Following discussion with the NIH program advisors, we have been encouraged to apply for a phase 1 grant, call to action for the Heal initiative to find new diagnostic and non-drug treatments for chronic pelvic pain.
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
Veera Health is helping 110M women in India get treated for Polycystic Ovary Syndrome (PCOS). Our app combines evidence-backed therapy with coaching & specialist support for a subscription fee. PCOS is the most common cause of infertility in women, and can lead to diabetes, depression and cancer. Patients spend up to 10 years and thousands of rupees searching for the right treatment, yet 90% are dissatisfied with existing options. With our program, 85% patients report feeling "in control" of their PCOS after just 1 month and are 4-times more likely to complete treatment. The founders, Shobhita (COO) and Shashwata (CEO) got an inside view into this massive need when the former was diagnosed with PCOS. Shashwata studied data science at Yale University, holds an MBA from Wharton, and helped grow Fortune 100 and growth-stage consumer health / product companies at McKinsey. Shobhita studied Biology & Psychology at Tufts University and has worked with leading healthcare companies, such as GlaxoSmithKline, Accenture Life Sciences & UnitedHealth.
Pre-clinical results published in the Journal of Neuro-Interventional Surgery. Technology presented at the World Live Neurovascular Conference. Technology selected as a top 3 finalist for Innovator of the Year by the Congress of Neurological Surgeons. Raised a Series A to fund commercialization (FDA Clearance, Health Canada, ISO 13485, First-in-man and early revenue).
Vena Vitals makes a small sticker that monitors blood pressure continuously. We've shown that it works in the operating room and is as accurate as the best tools doctors have today, at a fraction of the cost. We're a team of health tech scientists with multiple past startups and exits, and we've built products that have scaled to over 2M users.
We empower healthcare providers, starting with emergency physicians, with instant access to up-to-date evidence-based answers. Our platform cuts through the noise to deliver trustworthy medical information 10x faster, revolutionizing clinical decision-support.
We're building the nation's largest digital diabetes platform for underserved Americans. There are 80 million Americans on Medicaid and 30% or more have chronic disease. Less than 1% of patients with diabetes receive needed training. We provide a SMS-based telehealth platform to people with chronic disease on Medicaid. Our proven Healthy at Home program uses 2-way SMS interactions, weekly diabetes coaching visits, and evidence-based health education. Our vision is to reach millions of Americans that lack at-home support for chronic disease. We're billing health insurance $186 for telehealth visits and have 2 contracts underway. With your support, we can be a fully sustainable nonprofit by 2023.
Verge uses artificial intelligence and human data to develop better drugs faster. Verge has an end-to-end technology-driven drug discovery and development platform, featuring one of the field’s largest and most comprehensive proprietary patient genomics datasets from human tissue. Verge uses machine learning to mine this data and develops these insights into new drugs using it’s human-centric biology and chemistry platforms.
As healthcare costs have increased, the patient's home has become incredibly important as a site of care. Yet, patients recovering at home are highly underserved. Patients can only get better at home if they receive the high-quality care that they need reliably. The existing in-home care process involves patchwork of different vendors, all connected through faxes by nurses. We're building modern, robust software that solves this challenge and brings this market online.
At Verse Therapy, we're dedicated to making quality speech therapy accessible for everyone by empowering speech-language pathologists (SLPs) to launch and grow their own independent practices. We help therapists focus on what they do best—providing compassionate, personalized care—by taking care of the administrative tasks that often lead to burnout. Through thoughtful marketing and partnerships with care organizations like rehab centers, we connect SLPs with individuals who need their expertise. Our AI-enabled back office streamlines insurance processing, scheduling, and documentation, reducing non-therapy overhead. We're now live in 10 states with over 35 dedicated therapists and are in-network with leading insurance providers, making it easier for clients to receive the support they need.
Currently servicing the San Francisco Bay Area, Los Angeles, New York, Chicago, Washington DC, Baltimore, Atlanta, New Orleans and Tampa Bay. VetPronto is a new type of Veterinary Service dedicated to providing the most quality, convenient and transparent veterinary care possible. We're empowering vets across the country to better serve their patients. We treat pets at the home or workplace, saving them stress, and you time. We're using tech to provide a new standard of medical record management, client communication, and operational efficiency, including telemedicine and pharmacy integration.
If you're a YC company: Book Here! Calendly.com/ichra-vitablehealth We are a team of engineers, clinicians, and operators rethinking healthcare for startups and and SMB's. We make it simple for startups to offer ICHRA with built in direct primary care, including free virtual visits, over 1,000 prescriptions, and 40+ lab tests. Contributions are made with tax-free dollars, and we handle everything from onboarding to ongoing care so founders can stay focused on building. We are backed by world class investors like First Round Capital, Cherryrock, Y Combinator, and SoftBank, along with incredible founders and operators including Michael Seibel (YC, Twitch), Immad Akhund (Mercury), Allison Pickens (Gainsight), Jack Altman (Lattice), Dan Folkman (GoPuff), and others.
Vitalize Care is solving the most pressing operations problems for health systems, starting with optimizing staffing and scheduling. We help hospitals dramatically reduce labor spend, improve operational efficiency, and unburden clinical leaders from hours of work per day. We're partnered with some of the country's most innovative health systems, and are excited to share more details soon!
Our app allows doctors to speak any language, eliminating the need for human medical translators in hospitals and clinics. Despite spending billions on in-person and remote translators—mostly through outdated call centers—hospitals still fail to provide adequate care for non-English-speaking patients. We're building the most accurate and compliant medical language translation system across voice and video modalities.
Volt is an electrostimulation wearable to treat diseases like incontinence. The founder has already taken six medical devices to market, including the Cool Sculpting device that sold for billions. Incontinence affects 25 million people and is a $25 billion market. The device stimulates the muscles to get them the give feedback to receptors. This helps those suffering from incontinence to not pee when they don’t want to. The device can also target other conditions like migraines and comes with proprietary technology.
Volta Labs is a genomics applications company that has developed a cutting-edge digital fluidics platform to maximize performance and scalability of sample preparation in genomics while providing unparalleled consistency. Volta is transforming the way biological research and analyses are performed, allowing scientists to focus on what they do best -- pushing the boundaries of biology. As a collective of scientists and builders working at the intersection of engineering and biology, we imagine a world where extracting vital information from biological samples is as simple as pressing a button. That's our vision, and we're turning it into reality. Our HQ is in Boston’s Seaport, where we develop and manufacture our technology. We believe in cross-functional collaboration and continuous learning – whether your interest is in biology, MechEng, CompEng, or simply joining a fast-growing startup striving to make the world a better place, we'd love to welcome you to our team. Check out some of our blog posts to learn more about work life at Volta.
About Us Volumetric is a recognized world leader in building living multicellular tissues, with a focus on replicating discrete functions of the human body for basic mechanistic biology, laboratory testing and screening, and drug development. Founded in 2018 by Bagrat Grigoryan and Jordan Miller as a spin-out from Rice University, the full potential of our work is to build whole human organ replacements for patients, made from their own cells. Our Technology and Approach We have invented a suite of breakthrough 3D bioprinting technologies, featured on the cover of Science, that can build human tissue with complex blood vessel networks. We are leveraging this technology in the short term to build patient-specific tissues for drug safety and efficacy testing. Patient cells are taken from a biopsy, added to our proprietary 3D printed tissues, and then drug compounds are injected through the blood vessel network to mimic actual drug delivery in humans. Our vision is that our technology will provide rigorous, reproducible, and predictive outcomes for patients, resulting in drastically improved outcomes for diseases like cancer. More broadly, we see the full potential of our mission as being able to produce functional tissue and organ replacements for diseased or damaged vital organs in the body such as the lung, liver, pancreas, kidney, and heart.
